Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primaryAndrea Cavazzoni(University of Parma), Manuela Ferracin(University of Ferrara)Molecular TherapyJuly 19, 202410.1016/j.ymthe.2024.07.011Cited by 4SaveCiteExport RISWatch citationsRelated PapersCombined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines|Molecular Cancer|2012|45Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer|Cancers|2020|42